"The fact that people will be full of greed, fear or folly is predictable. The sequence is not predictable." - Financial Review, 1985
Warren BUFFETT
Donate with
Paypal
Selecting value stocks with BENJAMIN GRAHAM
Buy and sell alerts

Screening world Countries with Benjamin Graham
- U.S.A.
- Canada
- U.K.
- France
- Germany
- Japan
- Hong-Kong

Screening world Indexes with Benjamin Graham
Screening world Sectors with Benjamin Graham
My list of Value Stocks

Learning Value Investing with BENJAMIN GRAHAM


Value Investing with Benjamin Graham
Benjamin Graham's Formula
Defensive vs Enterprising Investors






Johnson&Johnson -

- DOW JONES 30 - Pharmaceuticals

Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. Johnson & Johnson has more than 250 operating companies. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics.

MARGIN OF SAFETY of Johnson&Johnson : 104.26 %
The Margin of Safety of Johnson&Johnson is OK (>50%).
How is the Margin of Safety calculated ?

QUALITY :
Conservative Investors : Earnings Stability OKEarnings Growth OK
Enterprising Investors : Financial Condition OKEarnings Stability OKDividends OKEarnings Growth OK

What are the Stars ?

FORUMS
VISIT Johnson&Johnson FORUM !
Alerts : no buy or sell alert
What are the alerts ?

Price over 1 year :

PRICE, INTRINSIC VALUE & MARGIN OF SAFETY based on GRAHAM's FORMULA
What is the Graham's Formula ?
Johnson&Johnson price is :
(as of 5/21/2009)
USD
Current Earnings per Share
(2009 est.) are :
USD
Estimated Long Term Growth
(% per Year) is :

%

INTRINSIC VALUE =
4.50 x (8.5 + 2 x 8.23) =

112.32 USD

MARGIN OF SAFETY =
(112.32 - 54.99 ) / 54.99 =

104.26 % (OK)

How is Long Term Growth estimated for Johnson&Johnson ?


Historical analysis for Johnson&Johnson - See detail



QUALITATIVE FILTERS FOR Johnson&Johnson
What are the Stars ?
DEFENSIVE
Earnings Stability OKEarnings Growth OK
ENTERPRISING
Financial Condition OKEarnings Stability OKDividends OKEarnings Growth OK
COMPANY SIZE (MKT CAP. Mls $) Very Large 150,922 mls.$ OK
The company's Market cap. is above 5000 millions dollars
-
FINANCIAL CONDITION Current Ratio 1.65
The current ratio is under 2

The current ratio is above 1.5
LT Debt/Net Curr. Assets 0.60
The LTdebt/current assets ratio is under 1

The LTdebt/current assets ratio is under 1.1
EARNINGS STABILITY Losses / 10 - 5 Years 0 / 0
No losses in the past ten years

No losses in the past five years
DIVIDENDS Years of Dividends 13
Less than 15 years of dividend in the past 15 years

Current dividends paid
EARNINGS GROWTH Growth 10-5 Years 177% / 88%%
Total Earnings growth above 33% for the past 10 years

Last year earnings above earnings 5 years ago
VALUATION P.E. x P/Book 43.31
P.E. x P/Book is above 22.5

P/Book is above 1.20
P.E. 12.2 OK
PE is under 15
-
P/Book 3.55 NO
P/Book is above 1.5
NO
P/Book is above 1.2

Johnson&Johnson - Competitors for Pharmaceuticals

 

STOCK QUALITY
Conservative Investors
MARGIN OF SAFETY
Long Term Growth
Price / Earnings

 

Forest Labs
- U.S.A.
SP 500
Pharmaceuticals
Financial Condition OKEarnings Stability OKEarnings Growth OKValuation OK
MARGIN OF SAFETY :
367.14 %
Long Term Growth : 11.15 %
Price / Earnings : 6.6 x
23.08 / 3.50 =
Sanofi Aventis
- France
CAC 40
Pharmaceuticals
Earnings Growth OKValuation OK
MARGIN OF SAFETY :
326.34 %
Long Term Growth : 11.13 %
Price / Earnings : 7.2 x
43.88 / 6.08 =
Biovail Corp
- Canada
TSE60
Pharmaceuticals
Valuation OK
MARGIN OF SAFETY :
214.09 %
Long Term Growth : 14.34 %
Price / Earnings : 11.8 x
14.56 / 1.23 =
Pfizer
- U.S.A.
DOW JONES 30
Pharmaceuticals
Earnings Stability OKDividends OKEarnings Growth OKValuation OK
MARGIN OF SAFETY :
212.11 %
Long Term Growth : 7.62 %
Price / Earnings : 7.6 x
14.83 / 1.95 =
Teva
- U.S.A.
Nasdaq 100
Pharmaceuticals
Earnings Stability OKEarnings Growth OK
MARGIN OF SAFETY :
161.19 %
Long Term Growth : 13.27 %
Price / Earnings : 13.4 x
44.28 / 3.30 =
Merck
- Germany
DAX 30
Pharmaceuticals
Earnings Stability OKEarnings Growth OKValuation OK
MARGIN OF SAFETY :
152.80 %
Long Term Growth : 10.97 %
Price / Earnings : 12.0 x
64.04 / 5.32 =
Astellas Pharma
- Tokyo
Nikkei 225
Pharmaceuticals
Earnings Stability OKDividends OKEarnings Growth OKValuation OK
MARGIN OF SAFETY :
148.84 %
Long Term Growth : 8.38 %
Price / Earnings : 10.1 x
3260 / 321.20 =
Bayer
- Germany
DAX 30
Pharmaceuticals
Dividends OKValuation OK
MARGIN OF SAFETY :
146.93 %
Long Term Growth : 10.23 %
Price / Earnings : 11.7 x
39.3 / 3.35 =
GlaxoSmithKline
- U.K.
FTSE 100
Pharmaceuticals
Earnings Stability OKEarnings Growth OK
MARGIN OF SAFETY :
134.07 %
Long Term Growth : 6.36 %
Price / Earnings : 9.1 x
1063.5 / 117.33 =
Sun Pharma
- India
Nifty50
Pharmaceuticals
Financial Condition OKEarnings Stability OKEarnings Growth OK
MARGIN OF SAFETY :
131.48 %
Long Term Growth : 13.45 %
Price / Earnings : 15.3 x
1290.6 / 84.39 =
Virbac
- France
Mid&Small 190
Pharmaceuticals
Earnings Stability OKEarnings Growth OK
MARGIN OF SAFETY :
127.68 %
Long Term Growth : 9.52 %
Price / Earnings : 12.1 x
52.36 / 4.33 =
Eli Lilly
- U.S.A.
SP 500
Pharmaceuticals
Earnings Stability OKDividends OKEarnings Growth OK
MARGIN OF SAFETY :
127.36 %
Long Term Growth : 5.10 %
Price / Earnings : 8.2 x
34.62 / 4.21 =
Wyeth
- U.S.A.
SP 500
Pharmaceuticals
Financial Condition OK
MARGIN OF SAFETY :
122.12 %
Long Term Growth : 9.76 %
Price / Earnings : 12.6 x
44.03 / 3.49 =
Takeda Pharm
- Tokyo
Nikkei 225
Pharmaceuticals
Earnings Stability OKDividends OKEarnings Growth OKValuation OK
MARGIN OF SAFETY :
122.01 %
Long Term Growth : 7.98 %
Price / Earnings : 11.0 x
3860 / 350.50 =
Abbott Labs
- U.S.A.
SP 500
Pharmaceuticals
Earnings Stability OKDividends OKEarnings Growth OK
MARGIN OF SAFETY :
110.19 %
Long Term Growth : 8.12 %
Price / Earnings : 11.8 x
43.32 / 3.68 =
Allergan
- U.S.A.
SP 500
Pharmaceuticals
Dividends OKEarnings Growth OK
MARGIN OF SAFETY :
106.31 %
Long Term Growth : 12.36 %
Price / Earnings : 16.1 x
43.79 / 2.72 =
Cipla Ltd
- India
Nifty50
Pharmaceuticals
Financial Condition OKEarnings Stability OKEarnings Growth OK
MARGIN OF SAFETY :
105.63 %
Long Term Growth : 12.73 %
Price / Earnings : 16.5 x
222.95 / 13.50 =
Johnson&Johnson
- U.S.A.
DOW JONES 30
Pharmaceuticals
Earnings Stability OKEarnings Growth OK
MARGIN OF SAFETY :
104.19 %
Long Term Growth : 8.23 %
Price / Earnings : 12.2 x
54.99 / 4.50 =
Eisai
- Tokyo
Nikkei 225
Pharmaceuticals
Earnings Stability OKDividends OKEarnings Growth OK
MARGIN OF SAFETY :
98.52 %
Long Term Growth : 9.42 %
Price / Earnings : 13.8 x
3050 / 221.50 =
Dr Reddys Labs
- India
Nifty50
Pharmaceuticals
Financial Condition OKEarnings Stability OKEarnings Growth OK
MARGIN OF SAFETY :
91.36 %
Long Term Growth : 10.82 %
Price / Earnings : 15.8 x
660.95 / 41.95 =
King Pharma
- U.S.A.
SP 500
Pharmaceuticals
Earnings Growth OKValuation OK
MARGIN OF SAFETY :
89.77 %
Long Term Growth : 4.21 %
Price / Earnings : 8.9 x
8.74 / 0.98 =
Shionogi
- Tokyo
Nikkei 225
Pharmaceuticals
Earnings Stability OKDividends OKEarnings Growth OK
MARGIN OF SAFETY :
81.75 %
Long Term Growth : 11.71 %
Price / Earnings : 17.6 x
1846 / 105.09 =
GlaxoSmith P
- India
Nifty50
Pharmaceuticals
Financial Condition OKEarnings Stability OKEarnings Growth OK
MARGIN OF SAFETY :
71.17 %
Long Term Growth : 11.32 %
Price / Earnings : 18.2 x
1096.25 / 60.25 =
Boiron
- France
Mid&Small 190
Pharmaceuticals
Earnings Stability OKDividends OKEarnings Growth OKValuation OK
MARGIN OF SAFETY :
56.40 %
Long Term Growth : 4.22 %
Price / Earnings : 10.8 x
19.5 / 1.80 =
Bristol Myers
- U.S.A.
SP 500
Pharmaceuticals
Financial Condition OKEarnings Stability OKDividends OK
MARGIN OF SAFETY :
32.57 %
Long Term Growth : 2.79 %
Price / Earnings : 10.6 x
20.39 / 1.92 =
Stallergenes
- France
Mid&Small 190
Pharmaceuticals
Earnings Stability OKEarnings Growth OK
MARGIN OF SAFETY :
2.07 %
Long Term Growth : 12.50 %
Price / Earnings : 32.8 x
47.58 / 1.45 =
Dainpn Sumi Phar
- Tokyo
Nikkei 225
Pharmaceuticals
Earnings Stability OKDividends OKEarnings Growth OKValuation OK
MARGIN OF SAFETY :
0.00 %
Long Term Growth : 0.00 %
Price / Earnings : 20.2 x
773 / 38.30 =
DAIICHI SANKYO
- Tokyo
Nikkei 225
Pharmaceuticals
Earnings Stability OK
MARGIN OF SAFETY :
0.00 %
Long Term Growth : 0.00 %
Price / Earnings : 28.6 x
1677 / 58.72 =
SH Dingli
- China
Shangaï-B
Pharmaceuticals
Earnings Growth OK
MARGIN OF SAFETY :
0.00 %
Long Term Growth : 0.00 %
Price / Earnings : 11.0 x
0.44 / 0.04 =
Cardiome Pharma
- Canada
SP/TSX Comp.
Pharmaceuticals
Financial Condition OK
MARGIN OF SAFETY :
0.00 %
Long Term Growth : 0.00 %
Price / Earnings : -13.7 x
4.66 / -0.34 =
Ipsen
- France
Mid&Small 190
Pharmaceuticals
Financial Condition OKEarnings Stability OK
MARGIN OF SAFETY :
0.00 %
Long Term Growth : 0.00 %
Price / Earnings : 19.3 x
32.17 / 1.67 =
Merck
- U.S.A.
DOW JONES 30
Pharmaceuticals
Earnings Stability OKDividends OK
MARGIN OF SAFETY :
0.00 %
Long Term Growth : 0.00 %
Price / Earnings : 8.1 x
26.12 / 3.22 =
Sepracor
- U.S.A.
Nasdaq 100
Pharmaceuticals
Valuation OK
MARGIN OF SAFETY :
0.00 %
Long Term Growth : 0.00 %
Price / Earnings : 5.7 x
14.23 / 2.48 =
Schering Plough
- U.S.A.
SP 500
Pharmaceuticals
MARGIN OF SAFETY :
0.00 %
Long Term Growth : 0.00 %
Price / Earnings : 13.8 x
23.68 / 1.72 =
Shire
- U.K.
FTSE 100
Pharmaceuticals
MARGIN OF SAFETY :
0.00 %
Long Term Growth : 0.00 %
Price / Earnings : 859.3 x
876.5 / 1.02 =
UCB
- Belgium
BEL20
Pharmaceuticals
Earnings Stability OKValuation OK
MARGIN OF SAFETY :
0.00 %
Long Term Growth : 0.00 %
Price / Earnings : 18.5 x
22.93 / 1.24 =
Watson Pharma
- U.S.A.
SP 500
Pharmaceuticals
Financial Condition OKValuation OK
MARGIN OF SAFETY :
0.00 %
Long Term Growth : 0.00 %
Price / Earnings : 12.3 x
29.85 / 2.42 =
CHUGAI PHARM
- Tokyo
Nikkei 225
Pharmaceuticals
Earnings Stability OKEarnings Growth OK
MARGIN OF SAFETY :
-17.60 %
Long Term Growth : 5.62 %
Price / Earnings : 24.0 x
1787 / 74.60 =
Kyowa Hakko K
- Tokyo
Nikkei 225
Pharmaceuticals
Financial Condition OKEarnings Stability OKDividends OKEarnings Growth OK
MARGIN OF SAFETY :
-44.33 %
Long Term Growth : 6.47 %
Price / Earnings : 38.5 x
966 / 25.09 =
Ranbaxy Labs
- India
Nifty50
Pharmaceuticals
Financial Condition OKEarnings Stability OKEarnings Growth OK
MARGIN OF SAFETY :
-85.47 %
Long Term Growth : 0.32 %
Price / Earnings : 62.9 x
220.25 / 3.50 =
AstraZeneca
- U.K.
FTSE 100
Pharmaceuticals
Earnings Stability OK
MARGIN OF SAFETY :
-94.72 %
Long Term Growth : 9.83 %
Price / Earnings : 533.5 x
2646 / 4.96 =